C. Janson (Uppsala, Sweden), J. Quint (Wimbledon, United Kingdom)
Late Breaking Abstract - Dysanapsis is a major determinant of airflow limitation among older adults
B. Smith (Montreal / New York, Canada), A. Benedetti (Montreal, Canada), N. Allen (Chicago, United States of America), A. Bertoni (Winsten-Salem, United States of America), M. Hilpert (New York, United States of America), D. Jacobs Jr. (Minneapolis, United States of America), J. Kaufman (Seattle, United States of America), C. Lin (Iowa City, United States of America), E. Michos (Baltimore, United States of America), E. Oelsner (New York, United States of America), K. Watson (Los Angeles, United States of America), E. Hoffman (Iowa City, United States of America), R. Barr (New York, United States of America)
|    |
Late Breaking Abstract - The population attributable risks (PAR) for chronic airflow obstruction (CAO) in 40 BOLD study centres worldwide.
P. Burney (London, United Kingdom), J. Patel (London, United Kingdom), C. Minelli (London, United Kingdom)
| |
Incidence of airflow obstruction over 20 years in Europe
S. Accordini (Verona, Italy), L. Calciano (Verona, Italy), A. Marcon (Verona, Italy), G. Pesce (Paris, France), J. Antó (Barcelona, Spain), A. Beckmeyer-Borowko (Basel, Switzerland), A. Corsico (Pavia, Italy), M. Imboden (Basel, Switzerland), C. Janson (Uppsala, Sweden), D. Keidel (Basel, Switzerland), F. Locatelli (Verona, Italy), C. Svanes (Bergen, Norway), D. Jarvis (London, United Kingdom), N. Probst-Hensch (Basel, Switzerland), C. Minelli (London, United Kingdom)
| |
Results from the Argentinean AATD Screening Program 2010-2017
V. Lorenzon (Buenos Aires, Argentina), S. Saez (Buenos Aires, Argentina), M. Fernandez Acquier (Buenos Aires, Argentina), G. Menga (Buenos Aires, Argentina), M. Fernandez (Buenos Aires, Argentina), J. Oyhamburu (Buenos Aires, Argentina), P. Sorroche (Buenos Aires, Argentina)
|  |
The impact of comorbidities on mortality in COPD, report from the OLIN COPD study.
S. Sawalha (Umeå, Sweden), L. Hedman (Umeå, Sweden), H. Backman (Umeå, Sweden), E. Rönmark (Umeå, Sweden), B. Lundbäck (Gothenburg, Sweden), N. Stenfors (Umeå, Sweden), A. Lindberg (Umeå, Sweden)
| |
Long-acting inhalation treatment and the risk of urinary tract infection – a symmetry analysis
D. Henriksen (Odense, Denmark), C. Laursen (Odense, Denmark), J. Sterndorf (Odense, Denmark), J. Davidsen (Odense, Denmark), J. Hallas (Odense, Denmark)
| |
The effect of inhaler switching on asthma and COPD patients
C. Bloom (London, United Kingdom), I. Douglas (London, United Kingdom), L. Smeeth (London, United Kingdom), J. Quint (London, United Kingdom)
| |
Comparing objective inhaler use among COPD and Asthma populations
H. Hoch (Aurora, United States of America), L. Kaye (San Francisco, United States of America), W. Anderson (Aurora, United States of America), R. Gondalia (San Francisco, United States of America), M. Barrett (San Francisco, United States of America), M. Tuffli (San Francisco, United States of America), D. Van Sickle (Madison, United States of America), S. Szefler (Aurora, United States of America), D. Stempel (San Francisco, United States of America)
| |
Persistence to COPD therapies and impact on exacerbations: a French claims data study
F. Dalon (Lyon, France), G. Devouassoux (Lyon, France), M. Belhassen (Lyon, France), G. Nachbaur (Rueil-Malmaison, France), C. Correia Da Silva (Rueil-Malmaison, France), L. Sail (Rueil-Malmaison, France), C. Chouaid (Créteil, France), E. Van Ganse (Lyon, France)
| |
The impact of patient characteristics on the Minimal Clinically Important Difference of COPD health status tools
H. Alma (Groningen, Netherlands), C. De Jong (Groningen, Netherlands), D. Jelusic (Bad Reichenhall, Germany), M. Wittmann (Bad Reichenhall, Germany), M. Schuler (Wuerzburg, Germany), R. Sanderman (Groningen, Netherlands), K. Schultz (Bad Reichenhall, Germany), J. Kocks (Groningen, Netherlands), T. Van Der Molen (Groningen, Netherlands)
| |
Follow-up desaturation in 6 minute walk tests and lung function decline in COPD patients
M. Waatevik (Bergen, Norway), T. Eagan (Bergen, Norway), F. Real (Bergen, Norway), J. Hardie (Bergen, Norway), P. Bakke (Bergen, Norway), B. Frisk (Bergen, Norway), A. Johannessen (Bergen, Norway)
| |
Impact of morning symptoms on 18-mo COPD outcomes across psychological distress status: a population-based study
G. Moullec (Montreal, Canada), W. Tan (Vancouver, Canada), P. Zhi Li (Montreal, Canada), N. Feigler (Mississauga, Canada), J. Bourbeau - On Behalf Of The Cancold Group (Montreal, Canada)
| |
Pneumonia vs non-pneumonia in COPD exacerbations – different risks?
G. Husebø (Bergen, Norway), R. Grønseth (Bergen, Norway), S. Lehmann (Bergen, Norway), B. Lærum (Bergen, Norway), T. Eagan (Bergen, Norway)
| |
Association between type 2 diabetes, prediabetes and lung function: Results from the KORA cohort
V. Jäger (Neuherberg, Germany), B. Thorand (Neuherberg, Germany), C. Huth (Neuherberg, Germany), K. Kahnert (Munich, Germany), W. Rathmann (Düsseldorf, Germany), A. Peters (Neuherberg, Germany), D. Nowak (Munich, Germany), R. Jörres (Munich, Germany), H. Schulz (Munich/Neuherberg, Germany), S. Karrasch (Munich/Neuherberg, Germany)
| |
Blood cell counts and C-reactive protein in relation to lung function in NHANES 2007-2010
E. Nerpin (Uppsala, Sweden), . JoãO (Porto, Portugal), T. Jacinto (Porto, Portugal), K. Alving (Uppsala, Sweden), C. Jansson (Uppsala, Sweden), A. Malinovschi (Uppsala, Sweden)
| |
Low dehydroepiandrosterone sulfate (DHEA-S) is associated with worse lung function in women.
G. Pesce (Paris, France), K. Triebner (Bergen, Norway), D. Van Der Plaat (Paris, France), D. Courbon (Paris, France), A. Marcon (Verona, Italy), S. Accordini (Verona, Italy), J. Anto (Barcelona, Spain), S. Dorado-Arenas (Bizkaia, Spain), J. Gullon (Avilés, Spain), J. Sanchez-Ramos (Huelva, Spain), I. Pin (Grenoble, France), Þ. Gislason (Reykjavík, Iceland), K. Torén (Gothenburg, Sweden), B. Forsberg (Umeå, Sweden), E. Lindberg (Uppsala, Sweden), E. Zemp (Basel, Switzerland), R. Jogi (Tartu, Estonia), S. Dharmage (Melbourne, Australia), N. Probst (Basel, Switzerland), D. Jarvis (London, United Kingdom), J. Garcia-Aymerich (Barcelona, Spain), F. Gomez-Real (Bergen, Norway), B. Leynaert (Paris, France)
| |
Nontuberculous mycobacterial disease within UK primary care, 2006-2016
E. Axson (London, United Kingdom), C. Bloom (London, United Kingdom), M. Obradovic (Frankfurt, Germany), R. Van Der Laan (Utrecht, Netherlands), J. Quint (London, United Kingdom)
| |
Sex differences in bronchiectasis patient characteristics: an analysis of the EMBARC cohort
S. Finch (Dundee, United Kingdom), E. Polverino (Barcelona, Spain), F. Blasi (Milan, Italy), F. Ringshausen (Hannover, Germany), A. De Soyza (Newcastle, United Kingdom), M. Vendrell (Girona, Spain), P. Goeminne (Leuven, Belgium), W. Boersma (Alkmaar, Netherlands), C. Haworth (Barcelona, Spain), M. Murris-Espin (Toulouse, France), A. Dimakou (Athens, Greece), M. Loebinger (London, United Kingdom), R. Menendez (Valencia, Spain), A. Torres (Barcelona, Spain), T. Welte (Hannover, Germany), A. Hill (Edinburgh, United Kingdom), R. Wilson (London, United Kingdom), S. Elborn (London, United Kingdom), S. Aliberti (Milan, Italy), J. Chalmers (Dundee, United Kingdom)
| |